BACKGROUND: The additional value of azathioprine concomitant treatment on infliximab pharmacokinetics in children is not well described yet. AIMS: In the present study, we aimed to describe the relationship between thiopurine metabolite levels, infliximab trough levels, anti-IFX antibody formation, and clinical and laboratory markers of disease activity in pediatric patients with Crohn's disease, and to assess non-adherence. METHODS: Data were collected prospectively during repeated visits from pediatric patients followed for Crohn's disease in two Czech pediatric inflammatory bowel disease centers between January 2016 and June 2017. Thiopurine metabolites (6-thioguanine and 6-methylmercaptopurine) were measured by high-performance liquid chromatography. Infliximab trough levels and anti-IFX antibody serum levels were measured routinely by ELISA. The risk of loss of response to infliximab therapy was also assessed. RESULTS: A significant association between infliximab serum levels and 6-thioguanine erythrocyte levels was observed when tested as categorical variables (63 patients, 321 observations). To predict infliximab levels > 5 µg/mL, we propose a 6-thioguanine cutoff of 278 pmol/8 × 108 erythrocytes (sensitivity, 0.799; specificity, 0.347). A higher loss-of-response-to-infliximab rate (tested in a subgroup of 51 patients) was observed in patients with undetectable 6-thioguanine levels than in those with detectable levels (p = 0.026). Non-adherence to azathioprine therapy was suspected in 20% of patients. CONCLUSION: Thiopurine metabolite monitoring in pediatric patients with Crohn's disease is useful when optimizing combination therapy. Pediatric patients with undetectable 6-thioguanine levels are more likely to lose response to infliximab therapy. When targeting optimal infliximab levels, the 6-thioguanine cutoff levels in children appear to be higher than in adults.

Department of Pediatrics 2nd Faculty of Medicine Charles University Prague and Motol University Hospital 5 Uvalu 84 150 06 Prague 5 Czech Republic

Department of Pediatrics Faculty of Medicine and Dentistry Palacky University and University Hospital 1 P Pavlova 185 6 779 00 Olomouc Czech Republic

Institute of Medical Biochemistry and Laboratory Diagnosis General University Hospital and 1st Faculty of Medicine Charles University Prague Na Bojisti 3 Prague 2 121 08 Prague Czech Republic

Laboratory of Growth Regulators Palacky University Olomouc and Institute of Experimental Botany AS CR Slechtitelu 27 783 71 Olomouc Czech Republic

Zobrazit více v PubMed

Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. PubMed

Van Assche G, Magdelaine-Beuzelin C, D’Haens G, Baert F, Noman M, Vermeire S, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterol. 2008;134(7):1861–8.

Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, et al. Clinical trial: benefits and risks of immunomodulators and maitenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009;30(3):210–26. PubMed

Kierkus J, Iwanczak B, Wegner A, Dadalski M, Grzybowska-Chlebowczyk U, Lazowska I, et al. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60(5):580–5. PubMed

Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanantion for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterol. 2002;122:904–15.

Schaeffeler E, Fisher C, Dierk B, Wernet D, Klaus M, Eichelbaum M, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogen. 2004;14:407–17.

Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Gen. 1980;32:651–62.

Roblin X, Williet N, Peyrin-Biroulet L. Thiopurine metabolism in the era of combotherapy. Inflamm Bowel Dis. 2016;21(4):951–61.

Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13(6):1118–24. PubMed

Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterol. 2006;130:1047–53.

Moreau AC, Paul S, Del Tedesco E, Rinaudo-Gaujous M, Baukhadra N, Genin C, et al. Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory bowel disease: a meta-analysis. Inflamm Bowel Dis. 2014;20:464–71. PubMed

Dubinsky MC, Lamothe S, Ying Yang G, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterol. 2000;118:705–13.

Ruemmelle FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECCO/ESPHGAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–207.

Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007;5:209–14. PubMed

Ansari A, Hassan C, Duley J, Marinaki A, Shobowale-Bakre EM. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1743–50. PubMed

Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58(6):795–806. PubMed

Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, et al. Mathematical weighting of the pediatric Crohn’s disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 2012;18(1):55–62. PubMed

Hyams J, Markowitz J, Otley A, Rosh J, Mack D, Bousvaros A, et al. Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr. 2005;41(4):416–21. PubMed

Dervieux T, Boulieu R. Simultaneous determination of 6-thioguanine and methyl-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem. 1998;44(3):551–5. PubMed

Hawwa AF, Millership JS, Colier PS, McElnay JC. Development and validation of HPLC method for the rapid and simultaneous determination of 6-mercaptopurine and four of its metabolites in plasma and red blood cells. J Pharmaceut Biomed Anal. 2009;49:401–9.

Dervieux T, Meyer G, Barham R, Matsutani M, Barry M, Boulieu R, et al. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolited in patients receiving azathioprine/6-mercaptopurine therapy. Clin Chem. 2005;51(11):2074–84. PubMed

Fangbin Z, Xiang G, Liang D, Hui L, Xueding W, et al. Prospective evaluation of pharmacogenomics and metabolite measurements upon azathioprine therapy in inflammatory bowel disease. Medicine. 2016;95(15):e3326. PubMed PMC

Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterol. 2015;148(7):1320–9.

Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996–2003. PubMed PMC

van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, et al. Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease. J Crohn Colitis. 2018;12(11):1316–25.

Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterol. 2017;153(3):827–34.

Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017;46(2):142–9. PubMed

Drobne D, Kurent T, Golob S, Švegl P, Rajar P, Hanžel J, et al. Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(7):880–9. PubMed

Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, et al. Concomitant use if immunomodulators affects the durability of inflixima therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(10):1748–56. PubMed

van Rheen H, van Rheen PF. Long-term efficacy of anti-tumor necrosis factor agents in pediatric luminal Crohn’s disease: a systemic review or real-world evidence studies. Pediatr Gastroenterol Hepatol Nutr. 2020;23(2):121–31.

Hradsky O, Potuznikova K, Siroka J, Lerchova T, Urbanek L, Mihal V, et al. Prediction of thiopurine metabolite levels based on hematological and biochemical parameters. J Pediatr Gastroenterol Nutr. 2019;69(4):e105–10. PubMed

deBruyn JC, Jacobson K, El-Matary W, Carroll M, Wine E, Wrobel I, et al. Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease: A Canadian Multicenter Clinical Practice Experience. J Pediatr Gastroenterol Nutr. 2018;66(2):268–73. PubMed

Jongsma MME, Winter DA, Huynh HQ, Norsa L, Hussey S, Kolho K-L, et al. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr. 2020;179(12):1935–44. PubMed PMC

Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645–60. PubMed

Hemperly A, Vande CN. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018;57(8):929–42. PubMed

Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–46. PubMed

Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, et al. A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650–60. PubMed

Jones J, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, et al. Impact of concomitant immunomodulator treatment on efficacy and safety of anti-TNF therapy in Crohn’s disease: a meta-analysis of placebo controlled trials with individual patient-level data. Clin Gastroenterol Hepatol. 2015;13(3):2230–40.

Hommel KA, Davis CM, Baldassanp RN. Objective versus Subjective Assesment of Oral Medication Adherence in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2009;15:589–93. PubMed PMC

Pozler O, Chládek J, Malý J, Hroch M, Dědek P, Beránek M, et al. Steady-state of azathioprine during initiation treatement of pediatric inflammatory bowel disease. J Crohns Colitis. 2010;4(6):623–8. PubMed

Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1678–82. PubMed

Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferentioal metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohns Colitis. 2010;14:546–52.

Friedman AB, Brown SJ, Bampton P, Barclay ML, Chung A, Macrae FA, et al. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol i azathioprine/mercaptopurine nonresponders (AAA Study). Aliment Pharmacol Ther. 2018;47:1092–102. PubMed